Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 23;57(20):8664-70.
doi: 10.1021/jm5011397. Epub 2014 Oct 1.

Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors

Jennie A Hutton  1 , Victor Goncalves, James A Brannigan, Daniel Paape, Megan H Wright, Thomas M Waugh, Shirley M Roberts, Andrew S Bell, Anthony J Wilkinson, Deborah F Smith, Robin J Leatherbarrow, Edward W Tate
Affiliations
Free PMC article

Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors

Jennie A Hutton et al. J Med Chem. .
Free PMC article

Abstract

Inhibitors of Leishmania N-myristoyltransferase (NMT), a potential target for the treatment of leishmaniasis, obtained from a high-throughput screen, were resynthesized to validate activity. Crystal structures bound to Leishmania major NMT were obtained, and the active diastereoisomer of one of the inhibitors was identified. On the basis of structural insights, enzyme inhibition was increased 40-fold through hybridization of two distinct binding modes, resulting in novel, highly potent Leishmania donovani NMT inhibitors with good selectivity over the human enzyme.

PubMed Disclaimer

Figures

Chart 1
Chart 1. Leishmania-Selective Hits from Screening of a Subset of the Pfizer Compound File
Scheme 1
Scheme 1. Synthesis of 1
Reagents and conditions: (a) pyrrolidine, N-Boc-4-piperidone, EtOH, rt, 3 days, 80%; (b) NH4HCO2, EtOH, Pd/C, 2 h, 96%; (c) para-fluorophenylacetyl chloride, Et3N, THF, 2 h, 92%; (d) 6 M HCl, IPA, 2 h, 43%.
Scheme 2
Scheme 2. Synthesis of Aminoacylpyrrolidine 2
Reagents and conditions: (a) 9, TFA, DCM, 0 °C to rt, 24 h, 88%; (b) (i) 1-chloroethyl chloroformate, toluene, 110 °C, 3 h, (ii) MeOH, reflux, 30 min; (c) 12, EDCI, HOBt, DIPEA, DMF, 4 h, 55% over 2 steps; (d) LiBH4, THF, 3 h, 71%; (e) TFA, DCM, 2 h, 31%.
Figure 1
Figure 1
Inhibitor 1 (blue) bound in the peptide binding pocket of LmNMT (green). PDB code: 4cgn.
Figure 2
Figure 2
Inhibitor 2a (pink) bound in the peptide binding pocket of LmNMT (green). MyrCoA in blue. PDB code: 4cgl.
Scheme 3
Scheme 3. Synthesis of 2a and 2b
Reagents and conditions: (a) (i) oxalyl chloride, DCM, DMF, 0 °C, 30 min, (ii) 17, Et3N, LiCl, 15 h, 29%; (b) 9, TFA, DCM, 0 °C to rt, 24 h, 18a 36%, 18b 25%; (c) CO(OMe)2, NaOMe, DCM, 15 h, 10a 48%, 10b 40%.
Figure 3
Figure 3
Overlay of I 2b (cyan) and 2a (pink) bound in the peptide binding pocket of LmNMT obtained by alignment of the protein main chain atoms (distances in Å). PDB code for 2b: 4cyn.
Figure 4
Figure 4
(a) Overlay of binding modes of 1 (blue) and 2a (pink). (b) Proposed hybrid structures 19 and 20.
Scheme 4
Scheme 4. Synthesis of 19 and 20
Reagents and conditions: (a) 9, TFA, DCM, 0 °C to rt, 24 h, 79%; (b) SnCl2, EtOH, 2 h, 87% (c) R = H, Ac2O, Et3N, DCM, 2 h, 65%, R = pF-Ph para-fluorophenylacetyl chloride, Et3N, DCM, 2 h, 42%; (d) (i) 1-chloroethyl chloroformate, toluene, 110 °C, 3 h, (ii) MeOH, reflux, 30 min; (e) EDCI, HOBt, DIPEA, 12, DMF, 4 h, R = H 41% over 2 steps, R = cpF-Ph 43% over 2 steps; (f) LiBH4, THF, 3 h; (g) TFA, DCM, 2 h, R = H 61% over 2 steps, R = pF-Ph 34% over two steps.
Figure 5
Figure 5
Overlay of hits 1 (blue), 2 (pink), and hybrid 20 (white; PDB code 4cyo) bound to LmNMT obtained by alignment of the protein main chain atoms.
Scheme 5
Scheme 5. Synthesis of Acid 35
Reagents and conditions: (a) (i) Meldrum’s acid, pyridine, DCM, 0 °C, 30 min then rt, 15 h, (ii) EtOH, reflux, 2 h, 70%; (b) NaBH4, MeOH, 0 °C to rt, 1.5 h, 40%; (c) LiOH, MeOH/H2O 99%.
Scheme 6
Scheme 6. Synthesis of Alcohol 43
Reagents and conditions: (a) (i) oxalyl chloride, DCM, DMF, 0 °C, 30 min, (ii) 16, Et3N, LiCl, 15 h, 45%; (b) 9, TFA, DCM, 0 °C to rt, 24 h, 38a 40%; (c) CO(OMe)2, NaOMe, DCM, 15 h 36%; (d) SnCl2, EtOH, 2 h, quantitative; (e) para-fluorophenylacetyl chloride, Et3N, DCM, 2 h 55%; (f) (i) 1-chloroethyl chloroformate, toluene, 110 °C, 3 h, (ii) MeOH, reflux, 30 min; (g) DMC, 35, Et3N, DCM, 15 h, 27% over 2 steps; (h) LiBH4, THF, 2 h, 25%.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Leishmaniasis: Burden and Distribution; World Health Organization: Geneva, 2013; http://www.who.int/leishmaniasis/burden/en (accessed July 1, 2014).
    1. Alvar J.; Velez I. D.; Bern C.; Herrero M.; Desjeux P.; Cano J.; Jannin J.; den Boer M. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7, e35671. - PMC - PubMed
    1. den Boer M.; Argaw D.; Jannin J.; Alvar J. Leishmaniasis impact and treatment access. Clin. Microbiol. Infect. 2011, 17, 1471–1477. - PubMed
    1. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001, 6, 849–854. - PubMed
    1. Croft S. L.; Sundar S.; Fairlamb A. H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006, 19, 111–126. - PMC - PubMed

Publication types

MeSH terms

Substances